Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Src siRNA-DOPC
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intraperitoneal
01
Overview
Src siRNA-DOPC is a liposomal formulation of small interfering RNA (siRNA) designed to silence the expression of the non-receptor tyrosine kinase Src. The siRNA is encapsulated within neutral 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) liposomes, which serve as a delivery vehicle for systemic administration. Src is a critical mediator of signaling networks activated by chronic stress, specifically through the ADRB-PKA-Src axis, which promotes tumor growth, migration, and invasion in various cancers. By reducing Src protein levels through RNA interference, this therapeutic candidate aims to inhibit stress-mediated cancer progression and metastasis, particularly in epithelial ovarian cancer. The development of this asset is primarily associated with researchers at the University of Texas MD Anderson Cancer Center.
- Other names
- Src-targeted siRNA-DOPCSrc siRNA in DOPC liposomes
02
Targets
SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on Src siRNA-DOPC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Src siRNA-DOPC.